PCSK9 and systemic lupus erythematosus: Third, the long-term effect of PCSK9 on SLE risk has not been studied, which may be addressed by an observational cohort study evaluating the efficacy of evolocumab (the PCSK9 inhibitor) on SLE severity and complications in one to 5 years after evolocumab initiation.